Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T10506 |
PPAR agonist 1
|
PPAR | DNA Damage/DNA Repair; Metabolism |
PPAR agonist 1 is an agonist of PPAR α/γ, used for reducing blood glucose, lipid levels, reducing body weight, and lowering cholesterol. | |||
T63514 | PPARγ agonist 1 | ||
PPARγ agonist 1 是 PPARγ 的有效激动剂,能够高效的激活 hPPARγ ,并不引起完全激动,进而能够避免不良反应。PPARγ agonist 1 对代谢紊乱相关心血管疾病表现出研究潜力。 | |||
T62968 | PPARα/δ agonist 1 | ||
PPARα/δ agonist 1 是一种有效的 PPARα/PPARδ 双重激动剂,对 PPARα和 PPARδ 的 EC50 值分别为 7.0 nM 和 8.4 nM。PPARα/δ agonist 1 对 PPARγ 表现出很高的选择性 (EC50: 1316.1 nM)。PPARα/δ agonist 1 具有潜力进行非酒精性脂肪性肝炎的研究。 | |||
T62266 | PPARα agonist 1 | ||
PPARα agonist 1 是一种完整的、有效的 PPARα激动剂。 | |||
T60535 | PPARα/γ agonist 1 | ||
PPARα/γ agonist 1 是一种有效的双重 PPARα/γ部分激动剂,是用于研究血脂异常和糖尿病的有前途的化合物。PPARα/γ agonist 1 对 PPARα 和 PPARγ 的EC50值分别为 28 nM 和 69 nM。 | |||
T12528 |
Pparδ agonist 1
|
Others | Others |
Pparδ agonist 1 is an agonist of PPAR-δ(EC50 of 5.06 nM). | |||
T70367 | SNU-BP | ||
SNU-BP is an agonist of PPAR-gamma, inhibiting lipopolysaccharide (LPS)-induced NO production and pro-inflammatory cytokines. SNU-BP potentiates interleukin-4-induced arginase-1 expression, and promotes microglial polarization toward an M2 anti-inflammatory phenotype. | |||
T79231 | DSO-5a | PPAR | DNA Damage/DNA Repair; Metabolism |
DSO-5a为具口服活性的BB3激动剂,兼具效力与选择性。此化合物为DMAKO-00系列衍生物,能够通过BB3提升ppar-γ功能并促进ERK1/2的磷酸化。DSO-5a主要应用于糖尿病领域的研究。 | |||
T69671 | SR1903 TFA | ||
SR-1903 is a modulator of retinoic acid receptor-related orphan receptor γ (RORγ) and liver X receptor (LXR). It is an inverse agonist of RORγ and an agonist of LXR. It also binds to peroxisome proliferator-activated receptor γ (PPAR) but does not activate it. SR-1903 inhibits LPS-induced expression of triggering receptor expressed on myeloid cells 1 (TREM-1). It also inhibits LPS-induced expression of the LXR target genes IL-6 and IL-33 and increases expression of ABCG1, FASN, and SCD-1. SR-190... | |||
T79454 | Anti-NASH agent 1 | PPAR | DNA Damage/DNA Repair; Metabolism |
Anti-NASH agent 1 (compound 3d),Elafibranor衍生物,高效PPAR-α/δ激动剂,针对非酒精性脂肪性肝炎(NASH)。以3-10 mg/kg剂量,连续4周处理,能显著改善蛋氨酸胆碱缺乏(MCD)诱导的NASH小鼠高脂血症、肝脏脂肪变性及炎症状况,展现出低肝毒性和良好肝脏保护效能。 |